A systematic review and meta-analysis published in Archives of Dermatological Research quantifies the prevalence of sleep disturbances among patients with atopic dermatitis, highlighting substantial disease...
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
A multinational cross-sectional survey of children and adolescents with moderate-to-severe atopic dermatitis found substantial disease burden, with distinct physical and psychosocial impacts by age group.
...
In a randomized clinical trial, investigators evaluated whether hydrocolloid dressings offer improved scar appearance and healing convenience compared to daily petroleum ointment after dermatologic...
A new longitudinal study published in the Journal of the American Academy of Dermatology evaluated more than a decade of data from adults living with HIV, revealing a steady decline in dermatologic disease...
Two-year data from the long-term phase 3 ALLEGRO-LT study suggest ritlecitinib maintains long-term clinical efficacy with a manageable safety profile in patients with moderate to severe alopecia areata.
...
New findings from a large, pragmatic trial found that daily full-body emollient application beginning by 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis by 24 months.
...
A randomized clinical trial found that adding wrist-ankle acupuncture to standard pharmacological treatment significantly improved pain relief in patients with acute herpes zoster.
